Clinical trials: Postprandial Distress Syndrome
Functional Dyspepsia
DLBS2411 Treatment For Functional Dyspepsia
This is a 2-arm, prospective, double-blind, randomized and placebo-controlled study using DLBS2411 at a dose of 250 mg twice daily (before morning and evening meals), for a 4-week course of therapy, for the treatment of patients…
- Trial name
- NCT05248802
- Testing
- DLBS2411
- Where
- 8 sites in Indonesia
- Volunteers
- 106 people
- Sponsor
- Dexa Medica Group
Dyspepsia
Phase III, Long-term, Open-label Safety Study of Z-338
The primary objective of this study is to evaluate the long-term safety of 100 mg Z-338 TID in European subjects with FD.
- Trial name
- NCT01973790
- Testing
- Z-338
- Where
- 36 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 207 people
- Sponsor
- Zeria Pharmaceutical
Postprandial Distress Syndrome
Acotiamide vs Itopride in Postprandial Distress Syndrome
The goal of this study is to "To compare the efficacy and safety of Acotiamide versus Itopride in patient with post prandial distress syndrome type of functional dyspepsia"
- Trial name
- NCT07174297
- Testing
- Acotiamide
- Volunteers
- 152 people
- Sponsor
- Getz Pharma
Post Prandial Distress Syndrome
A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome
To assess the efficacy of 3 oral dosing regimens of ATI 7505 compared to placebo in patients with PDS by comparing at the end of Day 42 the percentage of patients in each treatment group who have had adequate relief of…
- Trial name
- NCT00630370
- Testing
- 20 mg ATI 7505, 40 mg ATI 7505, 80 mg ATI 7505
- Where
- 64 sites in United States, Canada and 1 more
- Volunteers
- 6 people
- Sponsor
- Procter and Gamble
Postprandial Distress Syndrome
A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
The goal of this clinical trial is evaluating the efficacy and safety of Lianxiaxiaopi Granules in participant population. The main questions it aims to answer are: 1.
- Trial name
- NCT06696261
- Testing
- Lianxiaxiaopi Granules, a simulated agent of Lianxiaxiaopi Granules
- Where
- 18 sites in China
- Volunteers
- 342 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd